Expression and prognostic impact of the protein tyrosine phosphatases PRL-1, PRL-2, and PRL-3 in breast cancer.

Br J Cancer · 2006 · PMC2360632 · PMID 16832410

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

In subset 1, patients with PRL-3-positive breast carcinomas showed a trend towards shorter DFS compared to patients with PRL-3-negative cancers (83±4 months (95% CI, 74–91) vs 89±8 months (95% CI, 74–105), respectively).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.